Plasma tissue factor and serum angiotensin II and the therapeutic effect of different dosages of fosinopril on chronic heart failure.
- Author:
Qilin MA
1
;
Lijie YANG
;
Tianlun YANG
;
Ming SUN
;
Shenbin WU
;
Yanggen NING
Author Information
1. Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Aged;
Angiotensin II;
blood;
Angiotensin-Converting Enzyme Inhibitors;
administration & dosage;
Chronic Disease;
Female;
Fosinopril;
administration & dosage;
Heart Failure;
blood;
drug therapy;
Humans;
Male;
Middle Aged;
Thromboplastin;
metabolism
- From:
Journal of Central South University(Medical Sciences)
2009;34(5):448-452
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To determine the relation between plasma tissue factor (TF) and serum angiotensin II(AngII) and the effect of different dosages of fosinopril on chronic heart failure(CHF).
METHODS:Thirty healthy controls and 35 CHF patients were recruited to observe AngII,TF, left ventricular ejection fractions(LVEF) and left ventricular end-systolic volume index (LVESVI) at baseline and 10 weeks after the treatment. The 35 patients were randomly assigned into 2 groups: A routine dosage fosinopril group received 10 mg once daily and a middle dosage group received 10 mg twice a day for 10 weeks.
RESULTS:Compared with the healthy controls, AngII,TF,and LVESVI significantly increased (P<0.01) and LVEF significantly decreased (P<0.01) in CHF patients. The TF was positively correlated with AngII(r=0.2491, P<0.01) in the patients. After the 10-week treatment with different dosages of fosinopril, AngII,TF,and LVESVI obviously decreased(P<0.05 or P<0.01) and LVEF significantly increased in the 2 groups (P<0.05 or P<0.01). The middle dosage group changed more than the routine dosage group (P<0.01).
CONCLUSION:TF is positively correlated with AngII in CHF patients. Fosinopril can greatly improve cardiac function and antagonize prethrobotic state,and the therapeutic effect improves with the dosage increase.
